186 related articles for article (PubMed ID: 32579280)
1. What next? A Bayesian hierarchical modeling re-examination of treatments for adolescents with selective serotonin reuptake inhibitor-resistant depression.
Suresh V; Mills JA; Croarkin PE; Strawn JR
Depress Anxiety; 2020 Sep; 37(9):926-934. PubMed ID: 32579280
[TBL] [Abstract][Full Text] [Related]
2. Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.
Strawn JR; Mills JA; Croarkin PE
J Child Adolesc Psychopharmacol; 2019 May; 29(4):250-255. PubMed ID: 30810350
[No Abstract] [Full Text] [Related]
3. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Brent D; Emslie G; Clarke G; Wagner KD; Asarnow JR; Keller M; Vitiello B; Ritz L; Iyengar S; Abebe K; Birmaher B; Ryan N; Kennard B; Hughes C; DeBar L; McCracken J; Strober M; Suddath R; Spirito A; Leonard H; Melhem N; Porta G; Onorato M; Zelazny J
JAMA; 2008 Feb; 299(8):901-913. PubMed ID: 18314433
[TBL] [Abstract][Full Text] [Related]
4. Combining selective serotonin reuptake inhibitors and cognitive behavioral therapy in youth with depression and anxiety.
Strawn JR; Mills JA; Suresh V; Peris TS; Walkup JT; Croarkin PE
J Affect Disord; 2022 Feb; 298(Pt A):292-300. PubMed ID: 34728290
[TBL] [Abstract][Full Text] [Related]
5. Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression.
Hilton RC; Rengasamy M; Mansoor B; He J; Mayes T; Emslie GJ; Porta G; Clarke GN; Wagner KD; Birmaher B; Keller MB; Ryan N; Shamseddeen W; Asarnow JR; Brent DA
J Am Acad Child Adolesc Psychiatry; 2013 May; 52(5):482-92. PubMed ID: 23622849
[TBL] [Abstract][Full Text] [Related]
6. A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.
Goodyer IM; Dubicka B; Wilkinson P; Kelvin R; Roberts C; Byford S; Breen S; Ford C; Barrett B; Leech A; Rothwell J; White L; Harrington R
Health Technol Assess; 2008 May; 12(14):iii-iv, ix-60. PubMed ID: 18462573
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sample.
Vitiello B; Emslie G; Clarke G; Wagner KD; Asarnow JR; Keller MB; Birmaher B; Ryan ND; Kennard B; Mayes TL; DeBar L; Lynch F; Dickerson J; Strober M; Suddath R; McCracken JT; Spirito A; Onorato M; Zelazny J; Porta G; Iyengar S; Brent DA
J Clin Psychiatry; 2011 Mar; 72(3):388-96. PubMed ID: 21208583
[TBL] [Abstract][Full Text] [Related]
8. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
Hjalmarsson L; Corcos M; Jeammet P
Encephale; 2005; 31(3):309-16. PubMed ID: 16142045
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study.
Kaplan EM
Clin Ther; 2002 Jul; 24(7):1194-200. PubMed ID: 12182262
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study.
Shamseddeen W; Clarke G; Keller MB; Wagner KD; Birmaher B; Emslie GJ; Ryan N; Asarnow JR; Porta G; Brent DA
J Child Adolesc Psychopharmacol; 2012 Feb; 22(1):29-36. PubMed ID: 22251024
[TBL] [Abstract][Full Text] [Related]
11. The impact of age on antidepressant response: A mega-analysis of individuals with major depressive disorder.
Strawn JR; Mills JA; Suresh V; Mayes T; Gentry MT; Trivedi M; Croarkin PE
J Psychiatr Res; 2023 Mar; 159():266-273. PubMed ID: 36774767
[TBL] [Abstract][Full Text] [Related]
12. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.
Entsuah AR; Huang H; Thase ME
J Clin Psychiatry; 2001 Nov; 62(11):869-77. PubMed ID: 11775046
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs.
Nemeroff CB; Entsuah R; Benattia I; Demitrack M; Sloan DM; Thase ME
Biol Psychiatry; 2008 Feb; 63(4):424-34. PubMed ID: 17888885
[TBL] [Abstract][Full Text] [Related]
14. Venlafaxine extended-release: a review of its use in the management of major depression.
Wellington K; Perry CM
CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
[TBL] [Abstract][Full Text] [Related]
15. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy, acceptability, and safety of medicinal, cognitive-behavioral therapy, and placebo treatments for acute major depressive disorder in children and adolescents: a multiple-treatments meta-analysis.
Ma D; Zhang Z; Zhang X; Li L
Curr Med Res Opin; 2014 Jun; 30(6):971-95. PubMed ID: 24188102
[TBL] [Abstract][Full Text] [Related]
17. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis.
Bauer M; Tharmanathan P; Volz HP; Moeller HJ; Freemantle N
Eur Arch Psychiatry Clin Neurosci; 2009 Apr; 259(3):172-85. PubMed ID: 19165525
[TBL] [Abstract][Full Text] [Related]
18. Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response.
Asarnow JR; Emslie G; Clarke G; Wagner KD; Spirito A; Vitiello B; Iyengar S; Shamseddeen W; Ritz L; Birmaher B; Ryan N; Kennard B; Mayes T; DeBar L; McCracken J; Strober M; Suddath R; Leonard H; Porta G; Keller M; Brent D
J Am Acad Child Adolesc Psychiatry; 2009 Mar; 48(3):330-339. PubMed ID: 19182688
[TBL] [Abstract][Full Text] [Related]
19. Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.
Shih YC; Bekele NB; Xu Y
Pharmacoeconomics; 2007; 25(10):843-62. PubMed ID: 17887806
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
Kennedy SH; Andersen HF; Lam RW
J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
